Major depression now believed to be caused by abnormalities in immune cells of the brain; may revolutionize next-generation psychiatric medication treatment, according to Hebrew University of Jerusalem researchers.
“Microglia” cells in the brain, acting as first and main form of active immune defense of central nervous system, may be a key to causing depression. Latest theory opens door to development of a new generation of anti-depressant medications.
Major depression, which afflicts one in six people at some point in their life, is the leading global cause of disability – surpassing cardiovascular and respiratory diseases, cancer and HIV/AIDS combined.
In a groundbreaking theoretical review paper published in the peer-reviewed journal, Trends in Neurosciences, researchers from the Hebrew University of Jerusalem suggest that “progress in the understanding of the biology of depression has been slow,” requiring expanding beyond the “abnormalities in the functioning of neurons.” The contribution of other brain cells — often neglected by researchers — may be more relevant in causing depression, according to psychobiology Prof. Raz Yirmiya, director of the Hebrew University’s Laboratory for PsychoNeuroImmunology, and senior author of the journal’s paper, titled “Depression as a microglial disease.” http://authors.elsevier.com/a/1RpN8botpXeIf
Recent research at the Hebrew University’s laboratory and elsewhere finds that some forms of depression may result from malfunctioning brain cells, termed “microglia.” “However,” Prof. Yirmiya cautions, “this does not mean that all sub-types of depression or other psychiatric diseases are originated by abnormalities in these cells.”
Prof. Yirmiya’s new research could have a profound impact on the future development of anti-depressant medications. Present drugs do not always have the desired effect on patients, so there is an urgent need to discover novel biological mechanisms and drug targets for diagnosing the root cause of depression and for treating depressed patients appropriately.
In Trends in Neuroscience, the Hebrew University researchers claim that diseased microglia can cause depression and drugs that restore the normal functioning of these cells can be effective as fast-acting anti-depressants.
Microglia, which comprise 10% of all brain cells, are the brain’s immune cells. They fight infectious bacteria and viruses in the brain. They also promote repairing and healing processes of damages caused by brain injury and trauma.
“Our views on microglia have dramatically changed over the last decade,” Prof. Yirmiya says. “We now know that these cells play a role in the formation and fine-tuning of the connections between neurons (synapses) during brain development, as well as in changes of these connections throughout life. These roles are important for normal brain and behavioral functions, including pain, mood and cognitive abilities.”
“Studies in humans, using post-mortem brain tissues or special imaging techniques, as well as studies in animal models of depression, demonstrated that when the structure and function of microglia change, these cells can no longer regulate normal brain and behavior processes and this can lead to depression,” Prof. Yirmiya says.
Indeed, changes in microglia occur during many conditions associated with high incidence of depression, including infection, injury, trauma, aging, autoimmune diseases such as multiple sclerosis and neurodegenerative diseases such as Alzheimer’s disease. In these conditions, microglia assume an “activated” state in which they become big and round, and secrete compounds that orchestrate an inflammatory response in the brain.
The shape and function of microglia can be also changed following exposure to chronic unpredictable psychological stress, which is one of the leading causes of depression in humans. Importantly, research in Prof. Yirmiya’s laboratory recently discovered that following exposure to such stress, some microglia die and the remaining cells appear small and degenerated.
These findings have both theoretical and clinical implications. According to the new theory, either activation or decline of microglia can lead to depression. Therefore, the same class of drugs cannot treat the disease uniformly.
Prof. Yirmiya asserts that a personalized medical approach should be adopted in which the status of the microglia in the individual patient should be established first. Based on this initial assessment, treatment with drugs that either inhibit the over-active microglia or stimulate the suppressed microglia should be employed.
Read more: New Depression Diagnosis and Treatment
The Latest on: Depression
[google_news title=”” keyword=”depression” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Depression
- New guidelines for depression care emphasize patient-centered approach in Canadaon May 8, 2024 at 1:33 pm
Psychiatrists and mental health professionals have a new standard for managing major depression, thanks to refreshed clinical guidelines published today by the Canadian Network for Mood and Anxiety ...
- Black Women Over 50: Menopause Could Be Causing Your Depressionon May 8, 2024 at 1:00 pm
Studies find that women transitioning through menopause are at a higher risk of developing depressive symptoms. One study in the Journal of Clinical Endocrinology & Metabolism revealed that Black ...
- Ketamine Noninferior to ECT for Outpatients With Major Depressionon May 8, 2024 at 12:44 pm
NEW YORK CITY -- Treatment with ketamine was noninferior to electroconvulsive therapy (ECT) for major depressive disorder, two meta-analyses showed, though it was inferior for patients hospitalized ...
- Alanis Morissette says she felt like she was 'slowly dying' amid postpartum depression: 'It's like your whole self disappears'on May 8, 2024 at 12:34 pm
The Canadian singer talked about her experience as a mother-of-three on the "Mom and Mind" podcast's latest episode.
- Psychedelic Toad Venom Shows Promise for New Depression Treatmenton May 8, 2024 at 12:00 pm
Scientists have mapped the structure of a psychedelic drug derived from the Colorado River toad, which seems to have antidepressant effects.
- Serotonergic neuron findings suggest possible treatment for depression-related infertilityon May 8, 2024 at 11:12 am
They identified signaling from serotonergic neurons as important for maintaining reproductive function by sensing glucose availability and subsequently enhancing the release of the reproductive ...
- New device that emits magnetic field may offer hope for treating depressionon May 8, 2024 at 9:38 am
A head-mounted device that generates an ultra-low frequency ultra-low magnetic field has been found to improve the symptoms of four male patients diagnosed with major depressive disorder. Future ...
- Psychedelic Toad Venom Could Be Used To Treat Depression Based On New Evidenceon May 8, 2024 at 9:36 am
Modern science has dreamed up a wide variety of treatments for depression, anxiety, and other mental issues, and researchers may have stumbled across a ...
- Psychedelic toxins from toads could treat depression and anxietyon May 8, 2024 at 8:00 am
By Corryn WetzelA psychedelic compound secreted by a poisonous toad could help treat depression and anxiety, according to a study in mice.When frightened, Colorado river toads (Incilius alvarius) ...
- New guidelines for depression care emphasize patient-centred approachon May 7, 2024 at 5:00 pm
Psychiatrists and mental health professionals have a new standard for managing major depression, thanks to refreshed clinical guidelines. Psychiatrists and mental health professionals have a new ...
via Bing News